All In Biotech

Free tool

FAERS Monitor: Voraxaze

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125327 or its brand name (Voraxaze, Glucarpidase). Reports on generic versions are filed under their own applications.

Reports

363

Serious

260

72% of reports

Hospitalization

85

Death reported

71

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use92
  • underdose62
  • laboratory test interference58
  • acute kidney injury36
  • blood creatinine increased34
  • toxicity to various agents34
  • drug effect incomplete33
  • rebound effect33
  • drug ineffective31
  • death27
  • renal failure25
  • mucosal inflammation23
  • drug level increased16
  • alanine aminotransferase increased15
  • false positive investigation result15

Reports by year received

View as table
YearReports
20071
20081
20101
20111
20139
20148
201517
201625
201716
201856
201918
202042
202141
202218
202333
202421
202523
202632

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,796 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
laboratory test interferenceSignal584620.83610.1243,873
false positive investigation resultSignal15874.4530.712,046
rebound effectSignal33169.7122.55,354
drug level increasedSignal1656.134.7811
drug effect incompleteSignal3352.738.11,623
mucosal inflammationSignal2350.934.31,077
underdoseSignal6249.339.32,891
blood creatinine increasedSignal3430.221.9933
alanine aminotransferase increasedSignal1514.28.6171
acute kidney injurySignal3613.610.0412
toxicity to various agentsSignal3411.78.5324
renal failureSignal2510.97.5217
off label useSignal926.15.1403
death271.81.39
drug ineffective311.41.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.